Other Novel Treatment Approaches in Unresectable, Nonmetastatic HCC

Stephen Lam Chan, MBBS, MD, FRCP, FHKCP, FHKAM, and Gonzalo Cantis, MD, discuss additional emerging strategies that combine systemic agents with locoregional modalities. Chan highlights ongoing exploration of alternative immune checkpoint–based regimens and targeted therapies aimed at improving local and systemic control. Cantis underscores the need to define optimal sequencing, duration, and combinations to balance efficacy with hepatic safety in this vulnerable population.